

Peer-reviewed scientific papers

- Bartolomeo N, Barbosa M, Pannatier Schuetz Y, Castro DG, Nascimbeni AC, Barry MP, Ambresin A. Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degeneration. *Eur J Ophthalmol*. 2025 Dec 17;11206721251400508. doi: 10.1177/11206721251400508. Epub ahead of print. PMID: 41406248.
- Barbosa M, Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Barry MP, Ambresin A. Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool. *Int J Retina Vitreous*. 2025 Nov 19;11(1):126. doi: 10.1186/s40942-025-00751-9. PMID: 41258038; PMCID: PMC12628855.
- Zarranz-Ventura J, Ambresin A, Chang A, Dinah C, Holekamp NM, Rocha J, Saffar I, Singh RP. Establishing Expert Consensus on a Unified Decision Framework for Retina Patient Care. *Ophthalmol Ther*. 2025 Nov 15. doi: 10.1007/s40123-025-01269-x. Epub ahead of print. PMID: 41239161.
- Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebnetter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR; Swiss Retina Research Network. One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Ther*. 2025 Dec;14(12):3079-3091. doi: 10.1007/s40123-025-01252-6. Epub 2025 Oct 17. PMID: 41105325; PMCID: PMC12579096.
- Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, Ambresin A. Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence. *Ophthalmol Ther*. 2025 Sep 19. doi: 10.1007/s40123-025-01239-3. Epub ahead of print. PMID: 40971062.
- Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D. Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland. *J Med Econ*. 2025 Dec;28(1):1198-1213. doi: 10.1080/13696998.2025.2536420. Epub 2025 Jul 29. PMID: 40692491.
- Hatz K, Ambresin A, Schmid M, Prünke C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM; XTEND Study Group. Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration. *J Clin Med*. 2025 Mar 29;14(7):2370. doi: 10.3390/jcm14072370. PMID: 40217821; PMCID: PMC11989833.
- Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, Stillenmunkes R, Munk MR, Paris A, Menghini M, Artemiev D, Ebnetter A, Cattaneo J, de Oliveira Figueiredo EC, Eandi CM, Fröhlich J, Feltgen N, Spitznagel T, Somfai GM, Cozzi M, Zweifel S, Weinberger A, Garweg JG. One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Retina*. 2025 Mar 24:S2468-6530(25)00124-1. doi: 10.1016/j.oret.2025.03.015. Epub ahead of print. PMID: 40139459.
- Chitoroaga M, Pannatier Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Long-term Follow-up of Outer Retinal Microdefects (ORMDs) in Pachychoroid Pigment Epitheliopathy (PPE) and Sub-sequent Central Serous Chorioretinopathy (CSCR): A Report of Two Cases. *Klin Monbl Augenheilkd*. 2025. DOI: 10.1055/a-2500-5687. Epub ahead of print.
- Bartolomeo N, Déglise A, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Retinal Toxicity of Anticancer Drugs: a Case Series. *Klin Monbl Augenheilkd*. 2025. DOI: 10.1055/a-2521-4104
- Ben Ghezala I, Steinberg LA, Sibert M, Lazzarotti A, Ambresin A, Gabrielle PH, Creuzot-Garcher C. Temperature Excursion of Intravitreal Anti-VEGF Agents During Home Storage. *JAMA Ophthalmol*. 2025 Jan 16. doi: 10.1001/jamaophthalmol.2024.5884. Epub ahead of print. PMID: 39820629.

- Turgut F, Somfai GM, Tappeiner C, Hatz K, Mantel I, Ambresin A, Donati G, Guignard V, Nagyová D, Pfister IB, Schild C, Garweg JG. Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study. *Pharmaceuticals (Basel)*. 2024 Sep 19;17(9):1235. doi: 10.3390/ph17091235. PMID: 39338397; PMCID: PMC11434786.
- Vallée R, Körpe D, Vallée JN, Tsiropoulos GN, Gallo Castro D, Mantel I, Pournaras CJ, Ambresin A. Impact of preocular and ocular circulatory dynamics on the vascular density of retinal capillary plexuses and choriocapillaris. *Graefes Arch Clin Exp Ophthalmol*. 2024 Dec;262(12):3867-3879. doi: 10.1007/s00417-024-06544-4. Epub 2024 Jul 31. PMID: 39083077; PMCID: PMC11608175.
- Barbosa M, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Owlya N, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: A Report of Two Cases. *Klin Monbl Augenheilkd*. 2024 Apr;241(4):545-548. doi: 10.1055/a-2243-4802. Epub 2024 Apr 23.
- Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Castro DG, Ambresin A, Torpedo Maculopathy: Case Series of an Underdiagnosed and Rare Condition Using Multimodal Imaging, *Klin Monbl Augenheilkd*. 2024 Mar 26. doi: 10.1055/a-2238-7245. Online ahead of print.
- Pietzuch M, Mantel I, Ambresin A, Tappeiner C, Nagyova D, Donati G, Pfister IB, Schild C, Garweg JG. Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand. *J Ocul Pharmacol Ther*. 2023 Dec 20. doi: 10.1089/jop.2023.0105. Epub ahead of print. PMID: 38117666.
- Karmy BE, Castro DG, Ambresin A. Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab. *Klin Monbl Augenheilkd*. 2023 Apr;240(4):556-562. English. doi: 10.1055/a-2045-7844. Epub 2023 Apr 25. PMID: 37164395.
- Calci C, Castro DG, Schuetz YP, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated with Several Anti-VEGF Injections for Neovascular AMD: A Case Report. *Klin Monbl Augenheilkd*. 2023 Apr;240(4):478-480. English. doi: 10.1055/a-2004-5664. Epub 2023 Apr 25. PMID: 37164425.
- Tsiropoulos GN, Vallée R, Calci C, Gallo Castro D, Ambresin A. Patient Perspective on the Monitoring of Their Wet Age-Related Macular Degeneration during Coronavirus Disease 2019: A Retrospective Study. *Medicina (Kaunas)*. 2023 Mar 2;59(3):490. doi: 10.3390/medicina59030490. PMID: 36984491; PMCID: PMC10053385.
- Tsiropoulos GN, Castro DG, Ambresin A. Six Cases of Retinal Vascular Anomalies after Coronavirus Disease 2019: A Case Series. *Klin Monbl Augenheilkd*. 2022 Apr;239(4):537-544. English. doi: 10.1055/a-1771-5695. Epub 2022 Apr 26. PMID: 35472801.
- Tsiropoulos GN, Vallée R, Gallo Castro D, Ambresin A. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes. *J Fr Ophtalmol*. 2022 Oct;45(8):852-859. doi: 10.1016/j.jfo.2022.05.005. Epub 2022 Jul 6. PMID: 35908993; PMCID: PMC9257228.
- Moret E, Ambresin A, Gianniou C, Bijon J, Besse-Hayat C, Bogiatzi S, Hohl D, Spertini F, Mantel I. Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. *Graefes Arch Clin Exp Ophthalmol*. 2022 Mar;260(3):1005-1014. doi: 10.1007/s00417-021-05353-3. Epub 2021 Sep 16. PMID: 34529134; PMCID: PMC8850288.
- Bravetti GE, Vaudaux J, Pournaras JA, Ambresin A. Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema. *Klin Monbl Augenheilkd*. 2021 Apr;238(4):454-457. English. doi: 10.1055/a-1384-1056. Epub 2021 Apr 30. PMID: 33930917.
- Chatzistergiou V, Pappasavvas I, Ambresin A, Pournaras JC. Prediction of Postoperative Visual Outcome in Patients with Idiopathic Epiretinal Membrane. *Ophthalmologica*. 2021;244(6):535-542. doi: 10.1159/000517193. Epub 2021 Jun 1. PMID: 34062549.

- Zola M, Ambresin A, Zografos L. Optical Coherence Tomography Angiography Imaging of a Congenital Simple Hamartoma of the Retinal Pigment Epithelium. *Retin Cases Brief Rep.* 2021 May 1;15(3):289-293. doi: 10.1097/ICB.0000000000000788. PMID: 30074568.
- Chatzistergiou V, Ambresin A, Borruat FX. Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Secondary to Bowel Resection. *Klin Monbl Augenheilkd.* 2021 Apr;238(4):428-430. English. doi: 10.1055/a-1354-5816. Epub 2021 Feb 22. PMID: 33618384.
- Chatzistergiou V, Cilliers H, Pournaras JA, Ambresin A. Fovea Plana on Optical Coherence Tomography Angiography: New Perspectives. *Retina.* 2021 Jul 1;41(7):1541-1546. doi: 10.1097/IAE.0000000000003046. PMID: 33323906; PMCID: PMC8210783.
- Kuonen A, Bergin C, Ambresin A. Perifoveal capillary changes in diabetic patients and association between severity and type of diabetes, visual acuity, and enlargement of non-flow area in the retinal capillary plexuses. *J Fr Ophtalmol.* 2021 Mar;44(3):367-375. doi: 10.1016/j.jfo.2020.09.005. Epub 2021 Jan 23. PMID: 33494976.
- Gillmann K, Mansouri K, Ambresin A, Bravetti GE, Mermoud A. A Prospective Analysis of iStent Inject Microstent Implantation: Surgical Outcomes, Endothelial Cell Density, and Device Position at 12 Months. *J Glaucoma.* 2020 Aug;29(8):639-647. doi: 10.1097/IJG.0000000000001546. PMID: 32433094.
- Voide N, Mantel I, Ambresin A. Atypical Retro Internal Limiting Membrane Haemorrhage in Homozygous Sickle Cell Disease. *Klin Monbl Augenheilkd.* 2020 Apr;237(4):477-479. English. doi: 10.1055/a-1067-4141. Epub 2020 Feb 3. PMID: 32016938.
- Chatzistergiou V, Papasavvas I, Escher P, Durig J, Vaudaux J, Pournaras JA, Ambresin A. Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated with Oral Acetazolamide: Two Cases. *Klin Monbl Augenheilkd.* 2020 Apr;237(4):484-486. English. doi: 10.1055/a-1068-2762. Epub 2020 Feb 24. PMID: 32092772.
- Kheir V, Ambresin A, Mantel I. Multiple Serous Pigment Epithelial Detachments in Association With Major Weight Loss: Case Report and Review of the Literature. *Retin Cases Brief Rep.* 2020 Winter;14(1):72-76. doi: 10.1097/ICB.0000000000000624. PMID: 28834921.
- Roquelaure D, Rossi DC, Ambresin A, Guex-Crosier Y. Vasculitis and Retrofoveal Choroidal Neovessels in a Case of Multifocal Pattern Dystrophy. *Klin Monbl Augenheilkd.* 2019 Apr;236(4):523-525. English. doi: 10.1055/a-0831-2195. Epub 2019 Apr 18. PMID: 30999342.
- Sherif M, Berthoud J, Pournaras JA, Ambresin A. OCT-Angiography as a Help in the Diagnosis of a Laser Pointer Retinal Injury: A Case Report. *Klin Monbl Augenheilkd.* 2019 Apr;236(4):594-597. English. doi: 10.1055/a-0828-7449. Epub 2019 Feb 20. PMID: 30786287.
- Papasavvas I, Ambresin A, Pournaras JA, Henchoz L, Vaudaux J. Regression of Optic Disc Neovascularization (NVD) in a Patient with Behçet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA). *Klin Monbl Augenheilkd.* 2019 Apr;236(4):578-580. English. doi: 10.1055/a-0800-8066. Epub 2019 Jan 7. PMID: 30616283.
- Roemer S, Bergin C, Kaeser PF, Ambresin A. Assessment of Macular Vasculature of Children With Sickle Cell Disease Compared to That of Healthy Controls Using Optical Coherence Tomography Angiography. *Retina.* 2019 Dec;39(12):2384-2391. doi: 10.1097/IAE.0000000000002321. PMID: 30334922.
- Nguyen NCI, Fabro F, Ambresin A, Ezziat S, Bergin C, Mazzocato C, Mantel I. Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. *Eye (Lond).* 2018 Sep;32(9):1544-1546. doi: 10.1038/s41433-018-0126-z. Epub 2018 May 17. PMID: 29769650; PMCID: PMC6137149.
- Tam EK, Golchet P, Yung M, DeCroos FC, Spirn M, Lehmann-Clarke L, Ambresin A, Tsui I. Ischemic Central Retinal Vein Occlusion in the Anti-vascular Endothelial Growth Factor Era. *Retina.* 2018 Feb;38(2):292-298. doi: 10.1097/IAE.0000000000001546. PMID: 28207609.
- Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F. Acute Central Serous Chorioretinopathy: Factors Influencing Episode Duration. *Retina.* 2017 Oct;37(10):1905-1915. doi: 10.1097/IAE.0000000000001443. PMID: 28067724; PMCID: PMC5642321.

- Parvin P, Zola M, Dirani A, Ambresin A, Mantel I. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. *Graefes Arch Clin Exp Ophthalmol*. 2017 Nov;255(11):2127-2134. doi: 10.1007/s00417-017-3762-2. Epub 2017 Aug 10. PMID: 28798980; PMCID: PMC5640735.
- Kowalczyk L, Matet A, Dirani A, Daruich A, Ambresin A, Mantel I, Spaide RF, Turck N, Behar-Cohen F. Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic profile. *Retina*. 2017 Dec;37(12):2226-2237. doi: 10.1097/IAE.0000000000001424. PMID: 28002269; PMCID: PMC5732636.
- Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration. *Am J Ophthalmol*. 2015 Oct;160(4):732-8.e2. doi: 10.1016/j.ajo.2015.06.025. Epub 2015 Jul 2. PMID: 26144701.
- Ambresin A, Borruat FX. Hypertension artérielle et œil [Hypertension and the eye]. *Revue Medicale Suisse*. 2015 Dec 16;11(499):2366, 2368-72. French. PMID: 26852552.
- Matet A, Daruich A, Dirani A, Ambresin A, Behar-Cohen F. Macular Telangiectasia Type 1: Capillary Density and Microvascular Abnormalities Assessed by Optical Coherence Tomography Angiography. *Am J Ophthalmol*. 2016 Jul;167:18-30. doi: 10.1016/j.ajo.2016.04.005. Epub 2016 Apr 12. PMID: 27084003.
- de Massoungnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I. Pigment Epithelial Detachment Response to Aflibercept in Neovascular Age-related Macular Degeneration Refractory to Ranibizumab: Time Course and Drug Effects. *Retina*. 2016 May;36(5):881-8. doi: 10.1097/IAE.0000000000000813. PMID: 27115852.
- de Massoungnes S, Borruat FX, Ambresin A. Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a. *Klin Monbl Augenheilkd*. 2016 Apr;233(4):438-40. English. doi: 10.1055/s-0041-111803. Epub 2016 Apr 26. PMID: 27116503.
- Jang L, Gianniou C, Ambresin A, Mantel I. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. *Graefes Arch Clin Exp Ophthalmol*. 2015 Aug;253(8):1211-6. doi: 10.1007/s00417-014-2789-x. Epub 2014 Sep 30. PMID: 25267418.
- Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. *Eye (Lond)*. 2015 Mar;29(3):450-1. doi: 10.1038/eye.2014.321. Erratum for: *Eye (Lond)*. 2015 Mar;29(3):342-9. PMID: 25762129; PMCID: PMC4366476.
- Ambresin A, Strueven V, Pournaras JA. Painless indirect argon laser in high risk proliferative diabetic retinopathy. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):509-13. doi: 10.1055/s-0035-1545795. Epub 2015 Apr 22. PMID: 25902110.
- Dirani A, Mantel I, Ambresin A. Recurrent Macular Edema in Central Retinal Vein Occlusion Treated with Intravitreal Ranibizumab using a Modified Treat and Extend Regimen. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):538-41. doi: 10.1055/s-0035-1545746. Epub 2015 Apr 22. PMID: 25902116.
- Ladaique M, Dirani A, Ambresin A. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):542-7. doi: 10.1055/s-0035-1545817. Epub 2015 Apr 22. PMID: 25902117.
- Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22. PMID: 25902119.
- Meier PG, Ambresin A, Thirkill CE, Borruat FX, Schalenbourg A. Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):587-9. doi: 10.1055/s-0035-1545754. Epub 2015 Apr 22. PMID: 25902133.
- Mantel I, Niderprim SA, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. *Br J*

- Ophthalmol. 2014 Sep;98(9):1192-6. doi: 10.1136/bjophthalmol-2013-304556. Epub 2014 Apr 10. PMID: 24729031; PMCID: PMC4145421.
- Casparis H, Wolfensberger TJ, Becker M, Eich G, Graf N, Ambresin A, Mantel I, Michels S. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. *Retina*. 2014 Jan;34(1):12-7. doi: 10.1097/IAE.0b013e31829f74b0. PMID: 23945639.
 - Mantel I, Ambresin A, Moetteli L, Droz I, Roduit R, Munier FL, Schorderet DF. Complement factor B polymorphism and the phenotype of early age-related macular degeneration. *Ophthalmic Genet*. 2014 Mar;35(1):12-7. doi: 10.3109/13816810.2013.766217. Epub 2013 Feb 1. PMID: 23373431.
 - Ferrini W, Ambresin A. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. *Klin Monbl Augenheilkd*. 2013 Apr;230(4):423-6. doi: 10.1055/s-0032-1328388. Epub 2013 Apr 29. PMID: 23629796.
 - Vaclavik V, Borruat FX, Ambresin A, Munier FL. Novel maculopathy in patients with spinocerebellar ataxia type 1 autofluorescence findings and functional characteristics. *JAMA Ophthalmol*. 2013 Apr;131(4):536-8. doi: 10.1001/jamaophthalmol.2013.1127. PMID: 23579607.
 - Deli A, Moetteli L, Ambresin A, Mantel I. Comparison of fundus autofluorescence images acquired by the confocal scanning laser ophthalmoscope (488 nm excitation) and the modified Topcon fundus camera (580 nm excitation). *Int Ophthalmol*. 2013 Dec;33(6):635-43. doi: 10.1007/s10792-013-9749-z. Epub 2013 Mar 7. PMID: 23468053.
 - Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*. 2013 Mar;251(3):697-704. doi: 10.1007/s00417-012-2090-9. Epub 2012 Jun 26. PMID: 22733165.
 - Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*. 2011 Nov;249(11):1635-42. doi: 10.1007/s00417-011-1734-5. Epub 2011 Jul 2. PMID: 21725716.
 - Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of predominantly hemorrhagic lesions in exudative age-related macular degeneration. *Klin Monbl Augenheilkd*. 2011 Apr;228(4):288-92. doi: 10.1055/s-0031-1273214. Epub 2011 Apr 11. PMID: 21484631.
 - Moulin AP, Bucher M, Pournaras JA, Nguyen C, Ambresin A. Fluorescein and indocyanine green angiography findings in B cell lymphoblastic leukemia mimicking acute central serous chorioretinopathy. *Klin Monbl Augenheilkd*. 2010 Apr;227(4):342-4. doi: 10.1055/s-0029-1245251. Epub 2010 Apr 20. PMID: 20408096.
 - Konstantinidis L, Ambresin A, Zografos L, Mantel I. Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration. *Acta Ophthalmol*. 2010 Nov;88(7):736-41. doi: 10.1111/j.1755-3768.2009.01547.x. PMID: 19604160.
 - Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. *Eur J Ophthalmol*. 2010 Sep-Oct;20(5):955-8. doi: 10.1177/112067211002000524. PMID: 20306440.
 - Konstantinidis L, Zografos L, Mantel I, Ambresin A. Optimal treatment of retinal angiomatous proliferation. *Graefes Arch Clin Exp Ophthalmol*. 2010 Feb;248(2):289. doi: 10.1007/s00417-009-1159-6. Epub 2009 Aug 21. PMID: 19693530.
 - Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. *Graefes Arch Clin Exp Ophthalmol*. 2009 Nov;247(11):1567-9. doi: 10.1007/s00417-009-1117-3. PMID: 19727795.
 - Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). *Graefes Arch Clin Exp Ophthalmol*. 2009 Sep;247(9):1165-71. doi: 10.1007/s00417-009-1089-3. Epub 2009 Apr 29. PMID: 19404661.

- Polok B, Escher P, Ambresin A, Chouery E, Bolay S, Meunier I, Nan F, Hamel C, Munier FL, Thilo B, Mégardané A, Schorderet DF. Mutations in CNNM4 cause recessive cone-rod dystrophy with amelogenesis imperfecta. *Am J Hum Genet.* 2009 Feb;84(2):259-65. doi: 10.1016/j.ajhg.2009.01.006. Epub 2009 Feb 5. PMID: 19200527; PMCID: PMC2668018.
- Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. *Graefes Arch Clin Exp Ophthalmol.* 2009 Mar;247(3):311-8. doi: 10.1007/s00417-008-0995-0. Epub 2008 Nov 29. PMID: 19043731.
- Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. *Ophthalmologica.* 2008;222(5):321-3. doi: 10.1159/000144075. Epub 2008 Jul 11. PMID: 18617755.
- Mameletzi E, Pournaras JA, Ambresin A, Nguyen C. Retinal embolisation with localised retinal detachment following retrobulbar anaesthesia. *Klin Monbl Augenheilkd.* 2008 May;225(5):476-8. doi: 10.1055/s-2008-1027268. PMID: 18454403.
- Pournaras JA, Nguyen C, Vaudaux JD, Konstantinidis L, Ambresin A, Wolfensberger T. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results. *Klin Monbl Augenheilkd.* 2008 May;225(5):397-400. doi: 10.1055/s-2008-1027258. PMID: 18454380.
- Droz I, Mantel I, Ambresin A, Faouzi M, Schorderet DF, Munier FL. Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism. *Br J Ophthalmol.* 2008 Apr;92(4):513-7. doi: 10.1136/bjo.2007.127811. Epub 2008 Jan 22. PMID: 18211923.
- Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. *Eur J Ophthalmol.* 2006 Sep-Oct;16(5):705-10. doi: 10.1177/112067210601600507. PMID: 17061221.
- El Matri L, Ambresin A, Schorderet DF, Kawasaki A, Seeliger MW, Wenzel A, Arsenijevic Y, Borruat FX, Munier FL. Phenotype of three consanguineous Tunisian families with early-onset retinal degeneration caused by an R91W homozygous mutation in the RPE65 gene. *Graefes Arch Clin Exp Ophthalmol.* 2006 Sep;244(9):1104-12. doi: 10.1007/s00417-005-0096-2. Epub 2006 Feb 28. PMID: 16518657.
- Nessi F, Guex-Crosier Y, Ambresin A, Zografos L. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to toxoplasmic chorioretinal scar. *Klin Monbl Augenheilkd.* 2004 May;221(5):371-3. doi: 10.1055/s-2004-812860. PMID: 15162283.
- Ambresin A, Wolfensberger TJ, Bovey EH. Management of giant retinal tears with vitrectomy, internal tamponade, and peripheral 360 degrees retinal photocoagulation. *Retina.* 2003 Oct;23(5):622-8. doi: 10.1097/00006982-200310000-00003. PMID: 14574245.
- Ambresin A, Tran T, Spertini F, Herbort C. Behçet's disease in Western Switzerland: epidemiology and analysis of ocular involvement. *Ocul Immunol Inflamm.* 2002 Mar;10(1):53-63. doi: 10.1076/ocii.10.1.53.10326. PMID: 12461704.
- Ambresin A, Shaarawy T, Mermoud A. Deep sclerectomy with collagen implant in one eye compared with trabeculectomy in the other eye of the same patient. *J Glaucoma.* 2002 Jun;11(3):214-20. doi: 10.1097/00061198-200206000-00009. PMID: 12140398.
- Ambresin A, Borruat FX, Mermoud A. Recurrent transient visual loss after deep sclerectomy. *Arch Ophthalmol.* 2001 Aug;119(8):1213-5. PMID: 11483096